Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab
International Journal of Dermatology · 2025
DOI: 10.1111/ijd.17547 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift International Journal of Dermatology, 2025. Verfasst von Haruka Watanabe und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan. Hauptthemen laut MEDLINE: Omalizumab, Chronic Urticaria, Anti-Allergic Agents. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Background
Chronic spontaneous urticaria (CSU) exhibits notable responsiveness to omalizumab (OMA). The prognosis and subsequent therapeutic strategies warrant comprehensive exploration in cases exhibiting inadequate responses to OMA.
Methods
We conducted a multicenter retrospective analysis to investigate the 12‐month prognosis of patients inadequately responding to three injections of OMA. The endpoints encompassed identifying predictive factors for a favorable prognosis and assessing interventions related to an ameliorated prognostic outlook.
Results
The study involved 48 patients who met the inclusion criteria. After three OMA administrations, therapeutic interventions included the continuation of OMA in 34 patients, systemic corticosteroids in seven patients, and immunosuppressants in 12 patients. After 12 months, 28 of the 48 patients exhibited a good prognosis, whereas the remaining 20 displayed a less favorable prognosis. Good prognostic determinants encompassed the duration of CSU within 51 weeks, the presence of angioedema, IgE levels ≤100 IU/mL pre‐OMA, blood eosinophil counts ≥100/mm 3 post‐OMA, and urticaria control test (UCT) scores ≥5 pre‐OMA and ≥6 post‐OMA. Following the third OMA injection, the implementation of immunosuppressants presented an association with a good prognosis, while the employment of systemic corticosteroids correlated with an unfavorable prognosis.
Conclusions
More than half of patients inadequately responding to OMA achieved a good prognosis 12 months later. Several clinical variables appear to be predictive of prognosis, and certain therapeutic agents can be associated with prognostic outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Dermatology, Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima, Japan.
- Department of Dermatology, JA Hiroshima General Hospital, Hiroshima, Japan.
- Division of Cutaneous Science, Department of Dermatology, Nihon University School of Medicine, Tokyo, Japan.
- Division of Dermatology, Department of Internal Related, Kobe University Graduate School of Medicine, Kobe, Japan.
- Division of Medicine for Function and Morphology of Sensory Organs, Department of Dermatology, Faculty of Medicine, Osaka Medical and Pharmaceutical University, Osaka, Japan.
- Department of Dermatology, Course of Integrated Medicine, Graduate School of Medicine, Osaka University, Osaka, Japan.
ORCID-Profile: Shunsuke Takahagi
Zitieren
APA
Watanabe, H., Takahagi, S., Hayama, K., Fukunaga, A., Nakagawa, Y., Inomata, N., Chinuki, Y., & Hide, M. (2025). Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab. International Journal of Dermatology. https://doi.org/10.1111/ijd.17547
Vancouver
Watanabe H, Takahagi S, Hayama K, Fukunaga A, Nakagawa Y, Inomata N, et al. Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab. International Journal of Dermatology. 2025. doi:10.1111/ijd.17547
BibTeX
@article{Watanabe2025,
author = {Watanabe, Haruka and Takahagi, Shunsuke and Hayama, Koremasa and Fukunaga, Atsushi and Nakagawa, Yukinobu and Inomata, Naoko and Chinuki, Yuko and Hide, Michihiro},
title = {Prognosis of chronic spontaneous urticaria with an inadequate response to omalizumab},
journal = {International Journal of Dermatology},
year = {2025},
doi = {10.1111/ijd.17547}
}
EUVIMED